Opaleye Management Inc. is an SEC-registered investment adviser based in Boston, MA that reports managing 1 hedge fund on Form ADV. It reports $802.8 million in regulatory assets under management. Its private funds, of all types, hold $789.2 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +41.6% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +147.0% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $802.8 millionForm ADV Item 5.F
- Gross assets of private funds
- $789.2 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- 4Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 124513
- Latest Form ADV
- 02/19/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +39.5% | +14.8% |
| Q1 2026 | +1.6% | -4.6% |
| Q4 2025 | +11.2% | +2.4% |
| Q3 2025 | +39.4% | +7.8% |
| Q2 2025 | +6.3% | +10.4% |
| Q1 2025 | -16.7% | -4.5% |
| Q4 2024 | -6.0% | +2.1% |
| Q3 2024 | +35.0% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- Liquidia Corporation$195.1 million
- Eton Pharmaceuticals Inc$103.5 million
- Harrow Inc$101.9 million
- Disc Medicine Inc$62.5 million
- Urogen Pharma LTD$53.0 million
- Apogee Therapeutics Inc$51.8 million
- Meiragtx Hldgs PLC$48.0 million
- Sol Gel Technologies$37.1 million
- Rezolute Inc$32.8 million
- TG Therapeutics Inc$29.4 million
As of 2026-06-30, from 13F filing by Opaleye Management Inc..
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures